Radiation treatment for age-related macular degeneration

Seminars in Ophthalmology

Volumn 26, Issue 3, 2011, Pages 121-130

  Silva, Ruwan A ^a   Moshfeghi, Andrew A ^b   Kaiser, Peter K ^c   Singh, Rishi P ^c   Moshfeghi, Darius M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Age Related Macular Degeneration; Brachytherapy; Choroidal Neovascular Membrane; Radiation; Retina

Indexed keywords

PALLADIUM 103; PIGMENT EPITHELIUM DERIVED FACTOR; RANIBIZUMAB; RUTHENIUM 106; STRONTIUM 90; VASCULOTROPIN INHIBITOR; YTTRIUM 90;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; BRACHYTHERAPY; CATARACT; CATARACTOGENESIS; CHOROIDAL NEOVASCULAR MEMBRANE; CLINICAL TRIAL (TOPIC); ENDOTHELIUM CELL; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GENETIC PREDISPOSITION; HUMAN; INTRAOCULAR HEMORRHAGE; LOW ENERGY RADIATION; OPTIC NERVE; OPTIC NERVE DISEASE; PHACOEMULSIFICATION; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTON RADIATION; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION EXPOSURE; RADIATION SAFETY; RADIOSENSITIVITY; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINOPATHY; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL DISORDER; VISUAL IMPAIRMENT; VITRECTOMY;

ANIMALS; BRACHYTHERAPY; HUMANS; MACULAR DEGENERATION;

EID: 79957616216     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.3109/08820538.2011.554486     Document Type: Article

References (92)

1. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-572. (Pubitemid 38456293)
2. Ferris FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;102:1640-1642. (Pubitemid 15204559)
3. Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 1995;39:367-374.
4. Young RW. Pathophysiology of age-related macular degeneration. Surv Ophthalmol 1987;31:291-306. (Pubitemid 17076515)
5. Liutkeviciene R, Lesauskaite V, Asmoniene V, Zaliuniene D, Jasinskas V. Factors determining age-related macular degeneration: A current view. Medicina (Kaunas, Lithuania) 46:89-94.
6. Hammond BR, Wooten BR, Snodderly DM. Cigarette smoking and retinal carotenoids: implications for age-related macular degeneration. Vision Res 1996;3003-3009. (Pubitemid 26326610)
7. Klaver CC, Wolfs RC, Assink JJ, van Duijn CM, Hofman A, de Jong PT. Genetic risk of age-related maculopathy. Population-based familial aggregation study. Arch Ophthalmol 1998;116:1646-1651. (Pubitemid 29001964)
8. Meyers SM. A twin study on age-related macular degeneration. Trans Am Ophthalmol Soc 1994;92:775-843.
9. Smith W, Mitchell P. Family history and age-related maculopathy: The Blue Mountains Eye Study. Australian and New Zealand Journal of Ophthalmology 1998;26:203-206. (Pubitemid 28372494)
10. Almeida LN, Carolino RM, Sperandio DC, Nehemy MB, De Marco LA. The role of molecular genetic factors in age-related macular degeneration. Arquivos Brasileiros de Oftalmologia 2009;72:567-572.
11. Donoso LA, Kim D, Frost A, Callahan A, Hageman G. The role of inflammation in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 2006;51:137-152. (Pubitemid 43269939)
12. Arden GB, Wolf JE. Differential effects of light and alcohol on the electro-oculographic responses of patients with age-related macular disease. Invest Ophthalmol Vis Sci 2003;44:3226-3232. (Pubitemid 36759796)
13. Augustin AJ, Dick HB, Offermann I, Schmidt-Erfurth U. [The significance of oxidative mechanisms in diseases of the retina]. Klin Monatsbl Augenheilkd 2002;219:631-643. (Pubitemid 35285224)
14. Zhou J, Fonseca MI, Pisalyaput K, Tenner AJ. Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer's disease. Journal of Neurochemistry 2008;106:2080-2092.
15. Baird PN, Islam FM, Richardson AJ, Cain M, Hunt N, Guymer R. Analysis of the Y402H variant of the complement factor H gene in age-related macular degeneration. Invest Ophthalmol Vis Sci 2006;47:4194-4198. (Pubitemid 46591223)
16. Virgili G, Bini A. Laser photocoagulation for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2007;CD004763.
17. Moshfeghi DM, Kaiser PK, Grossniklaus HE, et al. Clinicopathologic study after submacular removal of choroidal neovascular membranes treated with verteporfin ocular photodynamic therapy. Am J Ophthalmol 2003;135:343-350. (Pubitemid 36279521)
18. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 1999;117:1329-1345.
19. Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trialstap report 2. Arch Ophthalmol 2001;119:198-207. (Pubitemid 32147926)
20. Arroyo JG, Michaud N, Jakobiec FA. Choroidal neovascular membranes treated with photodynamic therapy. Arch Ophthalmol 2003;121:898-903. (Pubitemid 36676231)
21. Axer-Siegel R, Ehrlich R, Yassur Y, et al. Photodynamic therapy for age-related macular degeneration in a clinical setting: Visual results and angiographic patterns. Am J Ophthalmol 2004;137:258-264. (Pubitemid 38220997)
22. Gremigni E, Falleni A, Belting C, Di Bartolo E, Rizzo S. Choroidal neovascular membranes after photodynamic therapy: Ultrastructural analysis of two surgically excised membranes. Eur J Ophthalmol 2004;14:555-561. (Pubitemid 40127971)
23. Michels S, Schmidt-Erfurth U. Sequence of early vascular events after photodynamic therapy. Invest Ophthalmol Vis Sci 2003;44:2147-2154. (Pubitemid 36520311)
24. Parodi MB, Da Pozzo S, Ravalico G. Angiographic features after photodynamic therapy for choroidal neovascularisation in age related macular degeneration and pathological myopia. Br J Ophthalmol 2003;87:177-183. (Pubitemid 36152744)
25. Schnurrbusch UE, Welt K, Horn LC, Wiedemann P, Wolf S. Histological findings of surgically excised choroidal neovascular membranes after photodynamic therapy. Br J Ophthalmol 2001;85:1086-1091. (Pubitemid 32835396)
26. Scupola A, Ventura L, Tiberti AC, D'Andrea D, Balestrazzi E. Histological findings of a surgically excised myopic choroidal neovascular membrane after photodynamic therapy. A case report. Graefes Arch Clin Exp Ophthalmol 2004;242:605-610. (Pubitemid 39157690)
27. Grisanti S, Tatar O, Canbek S, et al. Immunohistopathologic evaluation of choroidal neovascular membranes following verteporfin-photodynamic therapy. Am J Ophthalmol 2004;137:914-923. (Pubitemid 38582046)
28. Adams JA, Paiva KL, Munzenrider JE, Miller JW, Gragoudas ES. Proton beam therapy for age-related macular degeneration: Development of a standard plan. Med Dosim 1999;24:233-238.
29. Bora PS, Sohn J-H, Cruz JMC, et al. Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization. J Immunol 2005;174:491-497. (Pubitemid 40007439)
30. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT. Increased expression of angiogenic growth factors in agerelated maculopathy. Br J Ophthalmol 1997;81:154-162. (Pubitemid 27092496)
31. Timke C, Zieher H, Roth A, et al. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy. Clin Cancer Res 2008;14:2210-2219. (Pubitemid 351551134)
32. Kvanta A. Ocular angiogenesis: The role of growth factors. Acta Ophthalmol Scand 2006;84:282-288.
33. Shima DT, Adamis AP, Ferrara N, et al. Hypoxic induction of endothelial cell growth factors in retinal cells: Identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Molecular Medicine 1995;1:182-193.
34. van Wijngaarden P, Qureshi SH. Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age-related macular degeneration: A review of current practice. Clin Exp Optom 2008;91:427-437.
35. Vinores SA XW, Aslam S, Shen J, Oshima Y, Nambu H, Liu H, Carmeliet P, Campochiard PA. Implication of the hypoxia response element of the VEGF promoter in mouse models of retinal and choroidal neovascularisation, but not retinal vascular development. J Cell Physiol 2005;749-758. (Pubitemid 43191050)
36. Zhou J, Pham L, Zhang N, et al. Neutrophils promote experimental choroidal neovascularization. Mol Vis 2005;11:414-424. (Pubitemid 41410238)
37. Scholl HP, Fleckenstein M, Charbel Issa P, Keilhauer C, Holz FG, Weber BH. An update on the genetics of age-related macular degeneration. Mol Vis 2007;13:196-205. (Pubitemid 46232110)
38. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431. (Pubitemid 44511557)
39. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-335. (Pubitemid 41073112)
40. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444. (Pubitemid 44511558)
41. Gragoudas ES, Adamis AP, Cunningham ET, Jr., Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816. (Pubitemid 40051904)
42. Fowler J, Paliwal B, Kinsella T. 4th International Conference on Dose, Time, and Fractionation in Radiation Oncology, at the University of Wisconsin, Madison, WI, USA, 16-19 September 1992. Int J Radiat Biol 1993;63:271-273.
43. Finger PT, Berson A, Ng T, Szechter A. Ophthalmic plaque radiotherapy for age-related macular degeneration associated with subretinal neovascularization. Am J Ophthalmol 1999;127:170-177. (Pubitemid 29072557)
44. Finger PT, Berson A, Sherr D, Riley R, Balkin RA, Bosworth JL. Radiation therapy for subretinal neovascularization. Ophthalmology 1996;103:878-889. (Pubitemid 26190720)
45. Sivagnanavel V, Evans JR, Ockrim Z, Chong V. Radiotherapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2004;CD004004.
46. Garcia-Barros M, Paris F, Cordon-Cardo C, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003;300:1155-1159. (Pubitemid 36583102)
47. Imaizumi N, Monnier Y, Hegi M, Mirimanoff RO, Ruegg C. Radiotherapy suppresses angiogenesis in mice through TGF-betaRI/ALK5-dependent inhibition of endothelial cell sprouting. PloS one 2010 Jun 11;5(6):e11084.
48. Kakolyris S, Fox SB, Koukourakis M, et al. Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH39. British Journal of Cancer 2000;82:844-851. (Pubitemid 30085237)
49. Buchi ER, Lam TT, Suvaizdis I, Tso MO. Injuries induced by diffuse photodynamic action in retina and choroid of albino rats. Morphologic study of an experimental model. Retina 1994;14:370-378. (Pubitemid 24310159)
50. Ivanov VN, Zhou H, Ghandhi SA, et al. Radiation-induced bystander signaling pathways in human fibroblasts: A role for interleukin-33 in the signal transmission. Cell Signal 22:1076-1087.
51. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Three-year results from randomized clinical trials. . Arch Ophthalmol 1986;104(5):694-701.
52. Macular Photocoagulation Study Group. Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1990;108:816-824.
53. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1991;109:1232-1241.
54. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1991;109:1220-1231.
55. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study Year 1. Am J Ophthalmol 2008;145:239-248.
56. Silberman AW. Surgical debulking of tumors. Surgery, Gynecology & Obstetrics 1982;155:577-585. (Pubitemid 12034668)
57. Nieder C, Wiedenmann N, Andratschke N, Molls M. Current status of angiogenesis inhibitors combined with radiation therapy. Cancer Treat Rev 2006;32:348-364. (Pubitemid 44063875)
58. Evans JR, Sivagnanavel V, Chong V. Radiotherapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2010 May 12(5):CD004004.
59. Harino S, Oshima Y, Tsujikawa K, Oh A, Sugimoto K, Murayama S, Inoue T. [Treatment of age-related subfoveal choroidal neovascularization by low-dose external radiation: a preliminary study]. Nippon Ganka Gakkai Zasshi; 1997 Apr;101(4):341-348.
60. The Radiation Therapy for Age-related Macular Degeneration (RAD) Study group. A prospective, randomized, doublemasked trial on radiation therapy for neovascular age-related macular degeneration (RAD Study). Radiation Therapy for Age-related Macular Degeneration. Ophthalmology 1999 Dec;106(12):2239-2247.
61. Anders N, Stahl H, Dorn A, et al. [Radiotherapy of exudative senile macular degeneration. A prospective controlled study]. Ophthalmologe 1998;95:760-764.
62. Bergink GJ, Hoyng CB, van DMRW, Vingerling JR, van DWA, Deutman AF. A randomized controlled clinical trial on the efficacy of radiation therapy in the control of subfoveal choroidal neovascularization in age-related macular degeneration: Radiation versus observation. Graefes Arch Clin Exp Ophthalmol 1998;236:321-325. (Pubitemid 28192831)
63. Char DH, Irvine AI, Posner MD, Quivey J, Phillips TL, Kroll S. Randomized trial of radiation for age-related macular degeneration. Am J Ophthalmol 1999;127:574-578. (Pubitemid 29215769)
64. Ciulla TA, Danis RP, Klein SB, et al. Proton therapy for exudative age-related macular degeneration: A randomized, sham-controlled clinical trial. Am J Ophthalmol 2002;134:905-906. (Pubitemid 35425461)
65. Eter N, Schüller H. External beam radiotherapy for age- related macular degeneration causes transient objective changes in tear-film function. Graefes Arch Clin Exp Ophthalmol 2001;239:923-926. (Pubitemid 34026518)
66. Hart PM, Chakravarthy U, MacKenzie G, Archer DB, Houston RF. Teletherapy for subfoveal choroidal neovascularisation of age-related macular degeneration: Results of follow up in a non-randomised study. Br J Ophthalmol 1996;80:1046-1050. (Pubitemid 27010837)
67. Hart PM, Chakravarthy U, Mackenzie G, et al. Visual outcomes in the subfoveal radiotherapy study: A random-ized controlled trial of teletherapy for age-related macular degeneration. Arch Ophthalmol 2002;120:1029-1038. (Pubitemid 34856070)
68. Kobayashi H, Kobayashi K. Age-related macular degeneration: Long-term results of radiotherapy for subfoveal neovascular membranes. Am J Ophthalmol 2000;130:617-635.
69. Marcus DM, Peskin E, Maguire M, et al. The age-related macular degeneration radiotherapy trial (AMDRT): One year results from a pilot study. Am J Ophthalmol 2004;138:818-828. (Pubitemid 39452930)
70. Marcus DM, Sheils W, Johnson MH, et al. External beam irradiation of subfoveal choroidal neovascularization complicating age-related macular degeneration: One-year results of a prospective, double-masked, randomized clinical trial. Arch Ophthalmol 2001;119:171-180. (Pubitemid 32147923)
71. Valmaggia C, Ries G, Ballinari P. Radiotherapy for subfoveal choroidal neovascularization in age-related macular degeneration: A randomized clinical trial. Am J Ophthalmol 2002;133:521-529. (Pubitemid 34258061)
72. Evans JR, Sivagnanavel V, Chong V. Radiotherapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2010;5:CD004004.
73. Gragoudas ES, Li W, Lane AM, Munzenrider J, Egan KM. Risk factors for radiation maculopathy and papillopathy after intraocular irradiation. Ophthalmology 1999;106:1571-1577; discussion 1577-1578.
74. Zambarakji HJ, Lane AM, Ezra E, et al. Proton beam irradiation for neovascular age-related macular degeneration. Ophthalmology 2006;113:2012-2019. (Pubitemid 44635705)
75. Flaxel CJ, Friedrichsen EJ, Smith JO, et al. Proton beam irradiation of subfoveal choroidal neovascularisation in age-related macular degeneration. Eye 2000;14 (Pt 2):155-164. (Pubitemid 30265161)
76. Finger PT, Gelman YP, Berson AM, Szechter A. Palladium-103 plaque radiation therapy for macular degeneration: Results of a 7 year study. Br J Ophthalmol 2003;87:1497-1503. (Pubitemid 38010556)
77. Jaakkola A, Heikkonen J, Tommila P, Laatikainen L, Immonen I. Strontium plaque irradiation of subfoveal neovascular membranes in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 1998;24-30. (Pubitemid 28080567)
78. Jaakkola A, Heikkonen J, Tommila P, Laatikainen L, Immonen I. Strontium plaque brachytherapy for exudative age-related macular degeneration: Three-year results of a randomized study. Ophthalmology 2005;112:567-573. (Pubitemid 41108854)
79. Furdová A, Strmen P. [Brachytherapy in the treatment of age-related macular degeneration]. Bratisl Lek Listy 2000;101:234-236.
80. Sari B, Siki J, Katusi D, Vukojevi N. Brachytherapy-optional treatment for choroidal neovascularization secondary to age-related macular degeneration. Coll Antropol 2001;25 Suppl:89-96.
81. Avila MP, Farah ME, Santos A, et al. Twelve-month safety and visual acuity results from a feasibility study of intraocular, epiretinal radiation therapy for the treatment of subfoveal CNV secondary to AMD. Retina 2009;29:157-169.
82. Avila MP, Farah ME, Santos A, Duprat JP, Woodward BW, Nau J. Twelve-month short-term safety and visual-acuity results from a multicentre prospective study of epiretinal strontium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularisation secondary to age-related macular degeneration. Br J Ophthalmol 2009;93:305-309.
83. Moshfeghi DM, Kaiser PK, Gertner M. Stereotactic low- voltage x-ray irradiation for age-related macular degeneration. Br J Ophthalmol 2011 Feb;95(2):185-8.
84. Lee C, Chell E, Gertner M, et al. Dosimetry characterization of a multibeam radiotherapy treatment for age-related macular degeneration. Med Phys 2008;35:5151-5160.
85. Taddei P, Chell E, Hansen S, Gertner M, Newhauser W. Assessment of targeting accuracy of a low-energy stereotactic radiosurgery treatment for age-related macular degeneration. Phys Med Biol 2010;55:1-18.
86. Gertner M, Chell E, Pan KH, Hansen S, Kaiser PK, Moshfeghi DM. Stereotactic targeting and dose verification for age- related macular degeneration. Med Phys 2010;37:600-606.
87. Hanlon J, Lee C, Chell E, et al. Kilovoltage stereotactic radiosurgery for age-related macular degeneration: assessment of optic nerve dose and patient effective dose. Med Phys 2009;36:3671-3681.
88. Parsons JT, Fitzgerald CR, Hood CI, Ellingwood KE, Bova FJ, Million RR. The effects of irradiation on the eye and optic nerve. Int J Radiat Oncol Biol Phys 1983;9:609-622. (Pubitemid 13106623)
89. Parsons JT, Bova FJ, Fitzgerald CR, Mendenhall WM, Million RR. Radiation retinopathy after external-beam irradiation: Analysis of time-dose factors. Int J Radiat Oncol Biol Phys 1994;30:765-773. (Pubitemid 24355923)
90. Parsons JT, Bova FJ, Mendenhall WM, Million RR, Fitzgerald CR. Response of the normal eye to high dose radiotherapy. Oncology 1996;10:837-847; discussion 847-838, 851-832. (Pubitemid 126520853)
91. Eter N, Schüller H, Spitznas M. Radiotherapy for age-related macular degeneration: Is there a benefit for classic CNV? Int Ophthalmol 2001;24:13-19. (Pubitemid 34256670)
92. Kacperek A BM, Sheen MA and Damato BE. Macular degeneration treatment at Clatterbridge Centre for Oncology: Treatment and preliminary results. Phys Med Biol 2001;17:7-9.